Liberty Star Board Chair Pete O’Heeron & Director Gerardo King Interviewed by Steve Darling of Proactive Investors Limited TUCSON, AZ, April 16, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is executing on a vision that aligns with the long-term strategic needs of the United States. In a recent conversation with award-winning broadcaster Steve Darling of Proactive Investors, Board Chair Pete O’Heeron and Director Gerardo King shared why critical mineral development is no longer optional—it’s essential. Pete O’Heeron recently returned from Washington, D.C., where he held h...
Liberty Star Minerals Chairman Pete O’Heeron Engages with Congressional Leaders in D.C. to Champion U.S. Critical Mineral Independence TUCSON, AZ, April 10, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) (), a U.S. exploration company focused on strategic and commercially important critical minerals, today announced that Chairman of the Board Pete O’Heeron traveled to Washington, D.C. this week for a series of high-level meetings with Congressional offices to discuss the urgent need for U.S. investment in the exploration and development of critical minerals. While in the natio...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trendi...
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from ...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from dat...
NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against ModivCare, Inc. (“ModivCare” or the “Company”) (NASDAQ: MODV) and reminds investors of the March 31, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint ...
Moody's Ratings (Moody's) assigned a Caa2 rating to ModivCare Inc.'s new senior secured second lien PIK toggle notes due 2029 following the close of the company's exchange transaction. ModivCare's existing ratings, including its Caa1 corporate family rating (CFR), Caa1-PD probability of default rati...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to c...
Liberty Star Expands Leadership and Strengthens Exploration Team to Advance Red Rock Canyon and the Hay Mountain Projects TUCSON, AZ, March 12, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () strengthened its leadership and technical team to accelerate the advancement of its flagship gold and copper exploration projects. The Company is pleased to announce the engagement of Mr. Steve Rivera, an experienced consulting geologist and Qualified Person under USSEC S-K 1300, to provide senior geological management duties for the Red Rock Canyon (RRC) and Hay Mountain Projects. These...
Liberty Star Reports Significant 2024 Exploration Advancements at Hay Mountain & Red Rock Gold Projects; 2025 Focused on Expansion and Development TUCSON, AZ, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals (“” or the “”) () reflects on 2024 as a breakthrough year for exploration and positive discovery at its wholly owned Red Rock Canyon Gold Project () within its Hay Mountain Project () in southeast Arizona. The Company is actively pursuing a joint venture partnership to advance both projects, which lie within a regionally significant porphyry copper-gold-moly system extending fr...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary rev...
Liberty Star Chief Geologist Jim Bryce & Director Gerardo King Interviewed by Steve Darling of Proactive Investors Limited TUCSON, AZ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () updates its wholly owned Red Rock Canyon Gold Project (RRC) within its (HMP) in southeast Arizona. The projects may possess commercially important metals associated with porphyry copper-gold-moly geologic structures, well represented in the area from central Arizona to northern Mexico. The Company is pleased to announce that its Chief Geologist Jim Bryce and Board Director Gerardo King ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.